NeoGenomics - NEO Stock Forecast, Price & News

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Price Performance

NASDAQ:NEO traded down $0.39 during midday trading on Wednesday, hitting $11.69. The company had a trading volume of 13,760 shares, compared to its average volume of 2,264,459. NeoGenomics has a 52-week low of $6.85 and a 52-week high of $54.74. The stock's fifty day moving average price is $9.10 and its 200-day moving average price is $12.60. The company has a market capitalization of $1.47 billion, a PE ratio of -10.15 and a beta of 0.94. The company has a quick ratio of 7.26, a current ratio of 7.53 and a debt-to-equity ratio of 0.51.

NeoGenomics (NASDAQ:NEO - Get Rating) last announced its earnings results on Tuesday, August 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. NeoGenomics had a negative net margin of 30.00% and a negative return on equity of 8.53%. The company had revenue of $125.00 million during the quarter, compared to analyst estimates of $123.26 million. During the same period in the previous year, the business earned ($0.04) earnings per share. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, research analysts expect that NeoGenomics will post -1.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on NEO shares. Morgan Stanley reduced their price objective on shares of NeoGenomics from $19.00 to $18.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 10th. Needham & Company LLC reduced their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, August 10th. BTIG Research lowered shares of NeoGenomics to a "neutral" rating in a research note on Monday. The Goldman Sachs Group boosted their price target on shares of NeoGenomics from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, August 10th. Finally, StockNews.com upgraded shares of NeoGenomics to a "sell" rating in a research report on Saturday. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, NeoGenomics presently has a consensus rating of "Moderate Buy" and an average target price of $19.62.